...Francesco Facchiano; Daniela D’Arcangelo; Antonio Facchiano Introduction: Melanoma is the most aggressive skin cancer, with an increasing occurrence. Despite the recent important improvements due to novel immunotherapy approaches, when late diagnosed, melanoma prognosis is poor due...

...Amelia E. Sawyers; Anna C. Pavlick; Jeffrey S. Weber; Iman Osman; Jennifer A. Stein Objectives: Melanoma is one of the most common malignancies diagnosed during pregnancy. This study examined the impact of pregnancy on management decisions of melanoma patients treated at NYU Langone Health (NYULH...

... and proliferation. Dysregulation of NT/TRK signaling may affect neoplasm prognosis. Data on NT and TRK expression in melanomas are limited, and it is unclear whether NT/TRK signaling pathways are involved in the origin and progression of this neoplasm. Methods: We examined whether NT/TRK expression differs across...

...Zaid Al-Qurayshi; Sudesh Srivastav; Alun Wang; Erin Boh; John Hamner; Mohamed Hassan; Emad Kandil Objective: In this study, we aimed to examine the association of demographic and socioeconomic factors with cutaneous melanoma that required admission. Methods: A cross-sectional study utilizing...

...Kierstin Utter; Chloe Goldman; Sarah A. Weiss; Richard L. Shapiro; Russell S. Berman; Melissa Ann Wilson; Anna C. Pavlick; Iman Osman Background: Metastatic melanoma of unknown primary (MUP) is uncommon, biologically ill defined, and clinically understudied. MUP outcomes are seldom reported...

.... Here, we examine the impact of income on melanoma presentation and prognosis within a Caucasian cohort, accounting for ethnicity, as some reports suggest increased melanoma incidence in Ashkenazi Jewish (AJ) BRCA mutation carriers. Methods: We studied prospectively enrolled primary melanoma patients...

...Nathaniel H. Fleming; Jiaying Tian; Eleazar Vega-Saenz de Miera; Heidi Gold; Farbod Darvishian; Anna C. Pavlick; Russell S. Berman; Richard L. Shapiro; David Polsky; Iman Osman Objectives: Age is an understudied factor when considering treatment options for melanoma. Here, we examine the impact...

...-induced angiogenesis in several tumor types, including melanoma. Bevacizumab, a monoclonal antibody against VEGF, could be used as an imaging tool in preclinical studies. Objective: To radiolabel bevacizumab with [ 99m Tc(CO) 3 (OH 2 ) 3 ] + and evaluate it in vivo and in vitro for melanoma imaging...

...James M. Clark; Benjamin Kelley; Jill Titze; Henry Fung; John Maciejewski; Sunita Nathan; Elizabeth Rich; Sanjib Basu; Howard L. Kaufman Objective: High-dose interleukin-2 (IL-2) is effective immunotherapy for the treatment of metastatic melanoma and renal cell carcinoma (RCC) but has been...

...Itay Lazar; Riki Perlman; Michal Lotem; Tamar Peretz; Dina Ben-Yehuda; Luna Kadouri Objective: The inhibitor of apoptosis protein (IAP) livin is frequently overexpressed in melanoma. Livin binds caspases and thereby inhibits apoptosis. We found that caspases cleave livin to produce a truncated form...

...Satoru Aoyagi; Hiroo Hata; Erina Homma; Hiroshi Shimizu Objective: To determine the beneficial effect of maintenance therapy in stage II and III melanoma by sequential local injection of low-dose interferon-β. Methods: We reviewed 46 patients with stage II and III primary melanoma at our...

... alpha (ERα) gene and the body mass index, hypertension, coronary flow reserve, coronary atherosclerosis, and osteoporosis. There are currently no data examining the genetic polymorphisms of the ERα and estrogen receptor beta (ERβ) genes in melanoma patients. The aims of this study were to investigate...

...Ting J. Tu; Michelle W. Ma; Stefano Monni; Amy E. Rose; Herman Yee; Farbod Darvishian; David Polsky; Russell S. Berman; Richard L. Shapiro; Anna C. Pavlick; Madhu Mazumdar; Iman Osman Objective: Previous melanoma studies evaluating prognostic factors of survival at recurrence have focused...

...Brandon J. Metge; Suhu Liu; Adam I. Riker; Oystein Fodstad; Rajeev S. Samant; Lalita A. Shevde Objective: Breast cancer metastasis suppressor 1 (BRMS1) has been shown to functionally reduce the metastatic potential of melanoma. We also previously reported that BRMS1 negatively regulates...

... melanoma in mice. TNF-Α alone had marginal effect in vitro on melanoma cells. However, when this cytokine was combined with either Act D or IFN-Γ, synergistic cytostatic/ cytotoxic effects were observed. The highest cytotoxicity was demonstrated in cultures of melanoma cells in which all three agents...

.... In order to determine whether these factors are predictive of metastatic progression in melanoma, sIL-2R and IL-6 levels were measured in sera from 172 patients with melanoma and 60 in healthy controls. Mean sIL-2R values were significantly higher in the patients than in normal controls and the highest...

..., instructions or products referred to in the content or advertisements. Interleukin-2 Melanoma Renal cell carcinoma Biologic therapy T cell growth factor Interferon-α Nitric oxide Tumor necrosis factor Lymphokine-activated killer cells Tumor-infiltrating lymphocytes Oncology 1994;51:154- !69...

.... Interferon-α has been the most widely studied. The most encouraging results have been observed in the treatment of melanoma among nonhematological neoplasms, and in the locoregional treatment of other tumor types. It is hoped that further research into the use of the interferons, both singly...

... cell cancer Cutaneous T cell lymphoma Melanoma Breast cancer 30 6 2009 © 1994 S. Karger AG, Basel 1994 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form...

... differences or similarities in antigenic composition, CIC from 23 patients with gastrointestinal (GI) tumors, from 20 patients with stage III and IV melanoma and from 6 patients with inflammatory bowel disease (IBD) were studied. Serum from all GI, melanoma and IBD patients showed higher levels of CIC than...